sacituzumab
gilead sciences
['tropics-02', 'bcsm']
updated results from the phase 3 tropics-02 study demonstrated that the novel therapy improved os, orr, dor and overall quality of life compared with treatment of physician s choice. #bcsm #esmo22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.